Biotechnology - Rare diseases, Cardio-vascular


Popular Filters

Aegerion gains European approval for rare disease drug


The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

US FDA accepts Ruconest filing from Santarus and Pharming


US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder


The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Dezima Pharma in-licenses CETP inhibitor; Imaxio acquires Trolovol


Netherlands-based biotech firm Dezima Pharma says it has in-licensed a cholesteryl ester transfer protein…

BiotechnologyCardio-vascularDEZ-001Dezima PharmaImaxioLicensingMitsubishi TanabeRare diseasesSpiroleptTrolovol

FDA approves Aegerion's new orphan drug Juxtapid for rare cholesterol disorder


The US Food and Drug Administration has recently approved emerging US biotech firm Aegerion Pharmaceuticals'…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularJuxtapidlomitapideNorth AmericaRare diseasesRegulation

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments


US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro


The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Chelsea Thera gets disappointing news from FDA on Northera


US biotech firm Chelsea Therapeutics International (Nasdaq: CHTP) shares tumbled in pre-market trading…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRare diseasesRegulation

Back to top